Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

BACKGROUND: This analysis of the IMPACT study assessed the cardiovascular (CV) safety of single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI and UMEC/VI dual therapy. METHODS: IMPACT was a 52-week, randomized, double-blind, multicenter Phase III s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Respir Res
Main Authors: Day, Nicola C., Kumar, Subramanya, Criner, Gerard, Dransfield, Mark, Halpin, David M. G., Han, MeiLan K., Jones, C. Elaine, Kaisermann, Morrys C., Kilbride, Sally, Lange, Peter, Lomas, David A., Martin, Neil, Martinez, Fernando J., Singh, Dave, Wise, Robert, Lipson, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7275457/
https://ncbi.nlm.nih.gov/pubmed/32503599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-020-01398-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados